Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Han Han

Showing results (751-760 of 756) with videos related to

Pageof 76
Sort By:
You have reached the last page of results.This site can display upto 756 results.
Cancer Cell|March 19, 2020
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityJacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
Cancer Cell|October 8, 2019
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityJacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
Nature Cancer|June 18, 2021
ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancerJiehui Deng, Aatish Thennavan, Igor Dolgalev, et al.
Nature Communications|December 1, 2019
Genomic and immune profiling of pre-invasive lung adenocarcinomaHaiquan Chen, Jian Carrot-Zhang, Yue Zhao, et al.
The Journal of Clinical Investigation|December 24, 2024
Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer modelsDezhi Li, Ke Geng, Yuan Hao, et al.
Cancer Cell|December 30, 2019
CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung CancerHua Zhang, Camilla L Christensen, Ruben Dries, et al.
Pageof 76

Showing results (751-760 of 756) with videos related to

Sort By:
Pageof 76
You have reached the last page of results.This site can display upto 756 results.
Cancer Cell|March 19, 2020
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityJacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
Cancer Cell|October 8, 2019
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityJacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
Nature Cancer|June 18, 2021
ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancerJiehui Deng, Aatish Thennavan, Igor Dolgalev, et al.
Nature Communications|December 1, 2019
Genomic and immune profiling of pre-invasive lung adenocarcinomaHaiquan Chen, Jian Carrot-Zhang, Yue Zhao, et al.
The Journal of Clinical Investigation|December 24, 2024
Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer modelsDezhi Li, Ke Geng, Yuan Hao, et al.
Cancer Cell|December 30, 2019
CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung CancerHua Zhang, Camilla L Christensen, Ruben Dries, et al.
Pageof 76